search
Back to results

Parasternal vs. Sternotomy Approach for Conventional Aortic Valve Replacement (PASTA)

Primary Purpose

Aortic Valve Stenosis

Status
Unknown status
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Aortic valve replacement due to sternotomy
Aortic valve replacement due to parasternal right anterior mini-thoracotomy
Sponsored by
Jena University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Aortic Valve Stenosis focused on measuring Aortic Valve Stenosis, minimally invasive surgery, parasternal approach, quality of life, aortic valve replacement, inflammatory markers

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Indication for elective isolated aortic valve replacement
  • Anatomical suitability for both sternotomy and parasternal access
  • Age ≥ 18
  • Written informed consent in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion Criteria:

  • Planned simultaneous cardiac surgery interventions (Mitral valve surgery, tricuspid valve surgery, CABG, Pacemaker or defibrillator implantation, Pulmonalvenenisolation, Maze, closure of left atrial appendage , patent foramen ovale or atrial septal defect closure)
  • Acute myocardial infarction within 4 weeks, coronary heart disease
  • Acute endocarditis
  • TIA or stroke within 6 months prior to the procedure
  • Pregnant or breast-feeding women
  • Renal failure requiring dialysis
  • Ejection fraction ≤ 30%
  • Re-operation
  • Disease with a life expectancy < 2 years
  • Therapy with glucocorticoids or immunosuppressants

Sites / Locations

  • UKJRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Sternotomy AVR

Mini AVR

Arm Description

Aortic valve replacement due to sternotomy

Aortic valve replacement due to parasternal right anterior mini-thoracotomy

Outcomes

Primary Outcome Measures

Quality of life - physical function
Comparison of the physical quality of life between the two groups 30 days after surgery using the physical function score of the 36-Item Short Form Health Survey (SF-36). The physical function score is a scale from 0 (poor physical function) to 100 (excellent physical function, with an average score of 50. It includes items that assess physical functioning, bodily pain, physical role functioning, vitality, and generaly health perceptions.

Secondary Outcome Measures

Inflammatory markers: Procalcitonin, C-reactive protein, Interleukin-6
Plasma profiles of inflammatory biomarkers at defined time points in the course of the surgical intervention (baseline, before introduction of CPB, 1 hour after introduction of CPB, disconnection of CPB, 6, 24 and 48 hours post-surgery)
Quality of Life - mental function
Comparison of the mental quality of life between the two Groups 30 days after surgery using the mental component score of the 36-Item Short Form Health Survey (SF-36). The mental function score is a scale from 0 (poor mental quality of life) to 100 (excellent mental quality of life), with an average score of 50. It includes items that assess vitality, general health perceptions, emotional role functioning, social role functioning, and mental health.
Duration of the Operation
Comparison of the average duration of operation between the groups
Duration of cardiopulmonary bypass
Comparison of the average duration of cardiopulmonary bypass between the groups
Duration of aortic clamping
Comparison of the average duration of aortic clamping between the two groups
Major Adverse Cardiac and Cerebrovascular Events (MACCE)
A composite endpoint of mortality, myocardial infarction, urgent revascularization, stroke and major bleeding
Blood transfusion
A comparison of the number of transfusions between the groups
Rethoracotomy for bleeding
The incidence of rethoracotomy for bleeding after surgery
Post-operative pain
Measurement of patient's subjective assessment of their pain after surgery using a visual scale
Duration of mechanical ventilation
Comparison of the average duration of mechanical ventilation between the groups
Length of ICU stay
Comparison of the average number of days spent in Intensive Care Unit between the two groups
Length of hospital stay
Comparison of the average number of days spent in hospital between the groups
Atrial fibrillation
Incidence of new-onset atrial fibrillation after cardiac surgery
Wound infection
Incidence of wound infections
Mortality
intra- and postoperative mortality

Full Information

First Posted
November 6, 2020
Last Updated
March 22, 2021
Sponsor
Jena University Hospital
Collaborators
The German Heart Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT04632095
Brief Title
Parasternal vs. Sternotomy Approach for Conventional Aortic Valve Replacement
Acronym
PASTA
Official Title
Parasternal vs. Sternotomy Approach for Conventional Aortic Valve Replacement
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Unknown status
Study Start Date
March 16, 2021 (Actual)
Primary Completion Date
March 16, 2022 (Anticipated)
Study Completion Date
November 15, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jena University Hospital
Collaborators
The German Heart Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Prospective randomized study comparing aortic valve replacement using parasternal or sternotomy access with regard to quality of life and systemic inflammatory reaction.
Detailed Description
The classic surgical treatment of aortic stenosis is valve replacement through complete midline opening of the breastbone (median sternotomy) and use of cardiopulmonary bypass (CPB). Risks of this procedure are related to both the surgical approach and the use of CPB. Using minimally invasive approaches in non-cardiac patients (e.g laparoscopy) resulted in reduced postoperative inflammatory response when compared to patients undergoing the same procedures carried out with a conventional "open" technique. Minimally invasive surgical approaches in which the sternum is partially opened (partial sternotomy) or not opened at all (parasternal access) have thus far shown similar procedure related mortality and lower incidence of perioperative complications, despite longer CPB times. Our single center experience thus far suggests superiority of parasternal aortic valve replacement (O/E ratio of 0.19 over the last 2 years), as well as a reduced postoperative inflammatory response (as measured by lower CRP (C reactive protein ) levels taken 6 hours post-surgery). However, these data have several confounders and there is currently no prospective randomized trial addressing this topic. We therefore conduct a randomized comparison of parasternal versus classic sternotomy aortic valve replacement. Based on our previous experience, we expect very low mortality risk in both groups (expected ≤ 1%). The primary endpoint is therefore quality of life assessed using the SF-36 (Short Form) health survey questionnaire. This approach is similar to other current large multicenter trials. In order to address the impact of reduced surgical trauma on inflammatory response; we will quantify an established panel of inflammatory markers (PCT, CRP, interleukin 6) and use bio-banking to allow for further in depth analysis later on. Standardized clinical endpoints will be analyzed as additional secondary parameters. Power analysis determined a number of 50 patients allocated to 2 equal groups to achieve a power of 80%. The parasternal approach is expected to be superior when compared to sternotomy in both the primary and some, if not most, secondary endpoints. We expect our study to become an important milestone for decision-making in the treatment of aortic stenosis. Patients currently fear sternotomy, but the less invasive transcatheter valve implantation appears to be limited by inferior long-term outcome. The parasternal, sternotomy-sparing, classic aortic valve replacement is therefore an attractive therapeutic alternative. Our investigation in relation to systemic inflammatory response will further shed light on the underlying mechanisms explaining differences in clinical outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Valve Stenosis
Keywords
Aortic Valve Stenosis, minimally invasive surgery, parasternal approach, quality of life, aortic valve replacement, inflammatory markers

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Sternotomy AVR
Arm Type
Active Comparator
Arm Description
Aortic valve replacement due to sternotomy
Arm Title
Mini AVR
Arm Type
Active Comparator
Arm Description
Aortic valve replacement due to parasternal right anterior mini-thoracotomy
Intervention Type
Procedure
Intervention Name(s)
Aortic valve replacement due to sternotomy
Intervention Description
conventional surgery of aortic stenosis
Intervention Type
Procedure
Intervention Name(s)
Aortic valve replacement due to parasternal right anterior mini-thoracotomy
Intervention Description
surgery of aortic stenosis in minimally invasive technique
Primary Outcome Measure Information:
Title
Quality of life - physical function
Description
Comparison of the physical quality of life between the two groups 30 days after surgery using the physical function score of the 36-Item Short Form Health Survey (SF-36). The physical function score is a scale from 0 (poor physical function) to 100 (excellent physical function, with an average score of 50. It includes items that assess physical functioning, bodily pain, physical role functioning, vitality, and generaly health perceptions.
Time Frame
30 days after surgery
Secondary Outcome Measure Information:
Title
Inflammatory markers: Procalcitonin, C-reactive protein, Interleukin-6
Description
Plasma profiles of inflammatory biomarkers at defined time points in the course of the surgical intervention (baseline, before introduction of CPB, 1 hour after introduction of CPB, disconnection of CPB, 6, 24 and 48 hours post-surgery)
Time Frame
During the first 48 hours after surgery
Title
Quality of Life - mental function
Description
Comparison of the mental quality of life between the two Groups 30 days after surgery using the mental component score of the 36-Item Short Form Health Survey (SF-36). The mental function score is a scale from 0 (poor mental quality of life) to 100 (excellent mental quality of life), with an average score of 50. It includes items that assess vitality, general health perceptions, emotional role functioning, social role functioning, and mental health.
Time Frame
30 days after surgery
Title
Duration of the Operation
Description
Comparison of the average duration of operation between the groups
Time Frame
During the aortic valve replacement surgery
Title
Duration of cardiopulmonary bypass
Description
Comparison of the average duration of cardiopulmonary bypass between the groups
Time Frame
During the aortic valve replacement surgery
Title
Duration of aortic clamping
Description
Comparison of the average duration of aortic clamping between the two groups
Time Frame
During the aortic valve replacement surgery
Title
Major Adverse Cardiac and Cerebrovascular Events (MACCE)
Description
A composite endpoint of mortality, myocardial infarction, urgent revascularization, stroke and major bleeding
Time Frame
From the time of surgery until the patient is discharged from hospital, an average of 7 days
Title
Blood transfusion
Description
A comparison of the number of transfusions between the groups
Time Frame
From the time of surgery until the patient is discharged from hospital, an average of 7 days
Title
Rethoracotomy for bleeding
Description
The incidence of rethoracotomy for bleeding after surgery
Time Frame
From the time of surgery until the patient is discharged from hospital, an average of 7 days
Title
Post-operative pain
Description
Measurement of patient's subjective assessment of their pain after surgery using a visual scale
Time Frame
From the time of surgery until the patient is discharged from hospital, an average of 7 days
Title
Duration of mechanical ventilation
Description
Comparison of the average duration of mechanical ventilation between the groups
Time Frame
Measured from the time of arrival in the Intensive Care Unit until the time patients are extubated, an average of 12 hours
Title
Length of ICU stay
Description
Comparison of the average number of days spent in Intensive Care Unit between the two groups
Time Frame
From the time of surgery until the patient is discharged from hospital, an average of 30 days
Title
Length of hospital stay
Description
Comparison of the average number of days spent in hospital between the groups
Time Frame
From the time of surgery until the patient is discharged from hospital, an average of 30 days
Title
Atrial fibrillation
Description
Incidence of new-onset atrial fibrillation after cardiac surgery
Time Frame
From the time of surgery until the patient is discharged from hospital, an average of 7 days
Title
Wound infection
Description
Incidence of wound infections
Time Frame
During the first 30 days after surgery
Title
Mortality
Description
intra- and postoperative mortality
Time Frame
During the first 30 days after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Indication for elective isolated aortic valve replacement Anatomical suitability for both sternotomy and parasternal access Age ≥ 18 Written informed consent in accordance with Good Clinical Practice (GCP) and local legislation Exclusion Criteria: Planned simultaneous cardiac surgery interventions (Mitral valve surgery, tricuspid valve surgery, CABG, Pacemaker or defibrillator implantation, Pulmonalvenenisolation, Maze, closure of left atrial appendage , patent foramen ovale or atrial septal defect closure) Acute myocardial infarction within 4 weeks, coronary heart disease Acute endocarditis TIA or stroke within 6 months prior to the procedure Pregnant or breast-feeding women Renal failure requiring dialysis Ejection fraction ≤ 30% Re-operation Disease with a life expectancy < 2 years Therapy with glucocorticoids or immunosuppressants
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sophie Tkebuchava, MD
Phone
+4936419322928
Email
sophio.tkebuchava@med.uni-jena.de
First Name & Middle Initial & Last Name or Official Title & Degree
Torsten Doenst, MD
Phone
+4936419322901
Email
doenst@med.uni-jena.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sophie Tkebuchava, MD
Organizational Affiliation
University Hospital Jena
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Torsten Doenst, MD
Organizational Affiliation
University Hospital Jena
Official's Role
Principal Investigator
Facility Information:
Facility Name
UKJ
City
Jena
State/Province
Thueringen
ZIP/Postal Code
07747
Country
Germany
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Parasternal vs. Sternotomy Approach for Conventional Aortic Valve Replacement

We'll reach out to this number within 24 hrs